Efficacy of Linaclotide for Patients With Chronic Constipation Anthony J. Lembo, Caroline B. Kurtz, James E. MacDougall, B.J. Lavins, Mark G. Currie, Donald A. Fitch, Brenda I. Jeglinski, Jeffrey M. Johnston Gastroenterology Volume 138, Issue 3, Pages 886-895.e1 (March 2010) DOI: 10.1053/j.gastro.2009.12.050 Copyright © 2010 AGA Institute Terms and Conditions
Supplementary Figure 1 Diagram of patient flow through study. Gastroenterology 2010 138, 886-895.e1DOI: (10.1053/j.gastro.2009.12.050) Copyright © 2010 AGA Institute Terms and Conditions
Figure 1 Effects of linaclotide on bowel function, including spontaneous bowel movements (SBM), complete spontaneous bowel movements (CSBM), straining, and stool consistency. BSFS, Bristol Stool Form Scale. Gastroenterology 2010 138, 886-895.e1DOI: (10.1053/j.gastro.2009.12.050) Copyright © 2010 AGA Institute Terms and Conditions
Figure 2 Percentage of spontaneous bowel movements (SBM) and complete spontaneous bowel movement (CSBM) responders. CSBM and SBM responders were defined as a patient who, for 3 of the 4 treatment weeks, had a weekly CSBM (or SBM) rate ≥3 and an increase ≥1 relative to baseline. Gastroenterology 2010 138, 886-895.e1DOI: (10.1053/j.gastro.2009.12.050) Copyright © 2010 AGA Institute Terms and Conditions
Figure 3 Effects of linaclotide on abdominal symptoms (discomfort and bloating), constipation severity, and global relief of constipation. Gastroenterology 2010 138, 886-895.e1DOI: (10.1053/j.gastro.2009.12.050) Copyright © 2010 AGA Institute Terms and Conditions